Maligniteit als nevenbevinding bij de niet-invasieve prenatale test

Since 2017, the non-invasive prenatal test (NIPT) has been offered to all pregnant woman in the Netherlands in the context of the TRIDENT-2 study, which has been implemented as a trial within the Dutch national screening programme for Down’s, Edwards’ and Patau’s syndrome. The NIPT examines cell-free DNA in maternal blood. A small proportion of this DNA is of placental origin, but a vast proportion originates from the expectant mother. Findings other than the aforementioned syndromes are considered incidental. Occasionally, maternal malignancy is suspected in asymptomatic women as a result of aberrant NIPT results. In this case series, we present three patients with suspected malignancy based on NIPT results. We recommend the implementation of clinical guidelines for when this situation arises.

Conflict of interest and financial support: potential conflicts of interest have been reported for this article. ICMJE forms provided by the authors are available online along with the full text of this article.